Radiopharmaceutical · developed by Monopar Therapeutics
MNPR-101-DFO*-89Zr is a radiopharmaceutical administered intravenously for PET imaging. It is being studied in multiple solid tumors including bladder cancer, urothelial carcinoma, triple-negative breast cancer, lung cancer, colorectal cancer, gastric cancer, ovarian cancer, and pancreatic cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06337084 | Phase 1 | Solid Tumor, Adult | Active not recruiting | MNPR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder CancerColorectal CancerGastric CancerLung CancerOvarian CancerPancreatic CancerSolid Tumor, AdultTriple-negative Breast CancerUrothelial Carcinoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the MNPR page.
See MNPR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MNPR catalysts and pipeline →